SUMMARY OBJECTIVE: This study aimed to assess the sociodemographic and clinical profile of women deprived of their liberty and to identify the prevalence of sexually transmitted diseases and human papillomavirus through self-sampling samples. METHODS: This is an epidemiological, cross-sectional, observational, and descriptive study of the prevalence and correlation of the diagnosis of human papillomavirus infection in 268 encarcered women in Amazonas submitted to self-sampling from June 2019 to September 2020 using the genotyping analysis. Patients with positive and inconclusive results were evaluated by commercialized PCR to detect pathogens causing sexually transmitted diseases. The sample size used was based on a convenience sample. RESULTS: In 268 women, human papillomavirus DNA was detected in 87 (32.5%) of them. Sexually transmitted diseases were detected in 30 (34.48%) of the 87 women with a positive or inconclusive result for human papillomavirus. Women with more than three pregnancies had a higher risk of human papillomavirus detection (p=0.004). CONCLUSION: The prevalence of human papillomavirus and other sexually transmitted diseases in encarcered women in Amazonas is 32.5 and 34.48%, respectively. Most women were single (60.4%) and reported having had more than 15 partners (90.8%).

ABSTRACT Introduction: The assessment of the quality of life is considered important for a more humanistic and comprehensive treatment approach. Methods: This is a descriptive cross-sectional observational study using a quantitative approach. The quality of life of women undergoing immediate breast reconstruction after mastectomy at the Amazonas Oncology Control Center Foundation (Centro de Controle de Oncologia do Amazonas) from January to June 2015 was assessed. The assessment instrument used was the WHOQOL-BREF questionnaire, following the syntax of the WHOQOL Group. Results: The sociodemographic profiles of 22 patients were evaluated. The predominant age group was 45–49 years, the predominant educational level was high school (63.64%), 90.91% of the patients were from Manaus, and 72.73% were married. A total of 41% of the respondents defined their quality of life as good in the questionnaire, with the physical domain being the most affected and the social relationships domain being the less affected. Conclusion: The assessment of the quality of life should be prioritized in the choice of treatment for breast cancer.

RESUMO Introdução: A avaliação da qualidade de vida é importante para uma abordagem mais humana e abrangente. Métodos: Trata-se de um estudo observacional transversal descritivo com abordagem quantitativa que avaliou a qualidade de vida em mulheres submetidas à reconstrução mamária imediata após a mastectomia, no período de janeiro a junho de 2015, na Fundação Centro de Controle de Oncologia do Amazonas. O instrumento de avaliação foi o questionário WHOQOL-bref, seguindo a sintaxe do Grupo WHOQOL. Resultados: Foram avaliadas 22 pacientes, em relação ao perfil sócio demográfico, a faixa etária predominante foi de 45 a 49 anos, o ensino médio foi o mais frequente no estudo (63,64%) e em relação a procedência 90,91% das pacientes foram de Manaus, quanto a estado civil 72,73% eram casadas. Na avaliação através do questionário, a autoavaliação de qualidade de vida foi definida como boa em 41%, o domínio físico apresentou o maior comprometimento, enquanto o domínio de relações sociais foi o menos afetado. Conclusão: A avaliação da qualidade de vida deve ser parte primordial na escolha do tratamento do câncer de mama.

Abstract Hepatitis B infection is a global health issue. When considering patients with rheumatic diseases, this is no different. By using immunosuppressant drugs, such as DMARDs and biologics, viral reactivation is possible, leading to serious consequences on the patient. We report 3 cases of association between ankylosing spondylitis and hepatitis B with the use of immunosuppressant drugs. Case 1 was a patient with previous HBV infection using DMARD. Cases 2 and 3 were patients chronically infected by HBV during immunosuppressant therapy. The management of HBV infection during immunosuppressant therapy is challenging and needs multidisciplinary support.